title: Impact of prophylactic human papillomavirus vaccines on dermatology and venereology.
abstract: Prophylactic HPV L1 VLP quadrivalent and bivalent vaccines have a great importance for patients seen by dermatologists and venereologists. Both vaccines protect against HPV16- and HPV 18-associated anogenital cancers, as well as cancers of the mouth, the upper respiratory tract and skin, especially of the fingers and periungual region. The quadrivalent HPV6, 11, 16, 18 vaccine also prevents anogenital warts (condylomata acuminata) which are the most common benign tumors of this body region. HPV-vaccination (Gardasil) has been approved in Germany and other European Countries since October 2006 for young girls between 9-16 and young women between 16-26 years of age. Many experts feel that boys and young men should also be vaccinated. Men would profit from a vaccine that protects against HPV infections, especially anogenital warts, as well as penile and anal carcinomas. In immunosuppressed organ transplant recipients and HIV-positive patients. HPV disease can be widespread, chronic and often may rapidly progress to malignant tumors. Thus, these individuals would greatly benefit from prophylactic HPV immunization.
authors.affiliation: Department of Dermatology and Venereology, University of Rostock, Rostock, Germany. gerd.gross@med.uni-rostock.de
authors.forename: G
authors.initials: G
authors.lastname: Gross
mesh_terms: D000293:Adolescent; D000328:Adult; D052685:Alphapapillomavirus / Q000187:drug effects / Q000276:immunology; D001005:Anus Neoplasms / Q000517:prevention & control / Q000821:virology; D003218:Condylomata Acuminata / Q000517:prevention & control / Q000821:virology; D003880:Dermatology / Q000639:trends*; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D008297:Male; D010212:Papilloma / Q000517:prevention & control / Q000821:virology; D030361:Papillomavirus Infections / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D010412:Penile Neoplasms / Q000517:prevention & control / Q000821:virology; D011322:Primary Prevention / Q000379:methods; D012142:Respiratory Tract Neoplasms / Q000517:prevention & control / Q000821:virology; D012737:Sex Factors; D015229:Sexually Transmitted Diseases, Viral / Q000517:prevention & control; D017193:Skin Diseases, Viral / Q000517:prevention & control*; D014686:Venereology / Q000639:trends*; D014846:Vulvar Neoplasms / Q000517:prevention & control / Q000821:virology; D055815:Young Adult
chemical_list: D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines